Abenex has sold Inlog to Genii Software Group, a portfolio company of Bregal Unternehmerkapital
Inlog
Founded in 1992 and headquartered in Limonest, France, Inlog is a European leader in healthcare software, specializing in blood transfusion information systems, laboratory information systems and quality management systems. Its modular, Medical Device Regulation (MDR)-certified solutions support more than 600 public and private institutions across 12 countries, enabling mission-critical processes in blood banks, hospitals and laboratories.
Inlog’s ambition is to enhance patient health and optimize healthcare operations through secure, data-driven and interoperable solutions. The company’s platforms improve patient and donor safety, ensure full data traceability and strengthen regulatory compliance, while helping caregivers and institutions boost productivity and collaboration. Recognized for its innovation and environmental, social and governance (ESG) commitment as an “Entreprise à mission,” Inlog empowers healthcare systems to deliver safer, more reliable and more efficient care worldwide.
The Deal
GENII Software Group has acquired Inlog from Abenex and management, further strengthening its Laboratories division and consolidating its position as a leading European provider of specialized enterprise software. For Inlog, the transaction marks the beginning of a new growth chapter. Building on a successful transformation under Abenex, during which the company doubled its revenues, completed three strategic acquisitions and expanded into Germany and the Benelux, Inlog will now benefit from GENII’s scale and resources to accelerate revenue growth, expand internationally and drive product innovation, particularly in AI and cloud-based technologies.
Our Perspective
Matthieu Rosset, Managing Director in Lincoln’s Paris team, commented, “We are delighted to have supported Abenex and Inlog on this landmark transaction. Inlog has built a truly unique, patient-centric platform at the intersection of blood transfusion, laboratory management and quality systems. Its combination with GENII will accelerate international expansion and innovation while creating a stronger European leader in mission-critical healthcare software. This deal also highlights Lincoln’s deep expertise in healthcare software and our ability to deliver fast-paced competitive processes for financial sponsors.”
Abenex
Founded in 1992, Abenex is a long-standing player in the small and mid-cap private equity market, specializing in growth and buyout transactions in Europe, both as a minority and majority shareholder. Independent for 15 years, Abenex operates in three segments: positive impact private equity (small and mid-cap), decarbonization of small and medium-sized enterprises (SMEs) and sustainable real estate investments. In the small and mid-cap segments, Abenex is a long-term investor that partners with entrepreneurs and founding families and is operationally involved in growth and operational optimization projects. The team is made up of more than 45 professionals with proven and recognized expertise, located in Paris, Lyon, Milan and Amsterdam.
GENII Software Group
Headquartered in Munich, GENII Software Group is a leading provider of industry-specific software solutions tailored to the needs of mid-sized companies and public administrations. Operating through six business units (Manufacturing, Retail, Wholesale / Distribution, Automotive Aftermarket, Laboratories and Public Administration), GENII employs ~3,000 people across more than 35 locations and generates revenues of €400+ million. Its mission is to build a home for market-leading, specialized enterprise software that supports clients’ business-critical processes.
Bregal Unternehmerkapital
GENII Software Group is majority private equity-backed by Bregal Unternehmerkapital (BU), with additional support from Elvaston. BU is one of Europe’s leading middle market private equity firms, focusing on partnering with family businesses and entrepreneurs to drive growth and international expansion. With offices in Munich and Milan, BU manages more than €7 billion of assets and has built a strong track record across technology, industrials, healthcare and business services.
Through its vast software expertise and its extensive knowledge of blood transfusion and hospital laboratories ecosystems, Lincoln International has been instrumental in highlighting the differentiating aspects of Inlog’s mission-critical solutions and the development opportunities initiated by management under our ownership, while engineering a highly competitive process to deliver an optimized outcome for all the shareholders of the company.
Meet our Senior Team
Each transaction is unique and requires a tailor-made approach. Providing honest and straightforward advice is instrumental to develop mutually trustful relationships and reach the best outcome.
Matthieu Rosset
Managing Director & Co-Head of Technology, Europe
Paris
View More Transactions in Technology & Healthcare
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.